Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

235.25 7.93 +3.49%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 62.6×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC 8-K filed Oct 9, 2026

Period ended Oct 6, 2026 · Filed Oct 9, 2026 · accepted 9:02 AM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers

Red flags

Officer departure Oct 9, 2026
Jazz Pharmaceuticals PLC reported the departure of an officer or director

8-K filed Oct 9, 2026 · The filing · sec.gov